Table 1 Clinical characteristics of patients with hepatitis‑associated aplastic anaemia (HAAA).

From: Exploring strategies to optimise outcomes in hepatitis-associated aplastic anaemia patients following haematopoietic stem cell transplantation

Characteristics

HAAA

n = 35

Transplant year

 2008–2016

16 (45.7%)

 2017–2022

19 (54.3%)

Gender

 Male

24 (68.6%)

 Female

11 (31.4%)

Patient age at diagnosis, years, median (range)

23 (9–44)

Patient age at diagnosis, years

 9–19

15 (42.9%)

 20–29

11 (31.4%)

 30–39

8 (22.9%)

 40–

1 (2.9%)

Patient age at transplantation, years, median (range)

23 (9–44)

Diagnosis

 SAA

10 (28.6%)

 VSAA

23 (65.7%)

 NSAA

2 (5.7%)

CBC at diagnosis

 White blood cells, 109/L

0.97 (0.45–1.70)

 Neutrophils, 109/L

0.1550 (0.0200–0.4100)

 Hemoglobin, g/L

77 (68–86)

 Platelets, 109/L

10 (6–16)

 Reticulocytes, 1012/L

0.0093 (0.0050–0.01515)

Serum ferroprotein at diagnosis, ng/mL

567.85 (299.43–905.40)

Liver function at diagnosis of hepatitis

 ALT, IU/L

1282.00 (757.50–1765.00)

 AST, IU/L

847.50 (353.63–1151.25)

 TBIL, μmol/L

131.50 (31.70–234.00)

 DBIL, μmol/L

114.15 (47.18–153.68)

Interval from hepatitis to diagnosis, days, median (range)

60 (0–210)

PNH clone

3 (9.4%)a

Primary symptoms

 Mucocutaneous hemorrhage

21 (60.0%)

 Infections with or without fever

13 (37.1%)

 Fatigue only

6 (17.1%)

Lymphocyte subsets in peripheral blood at diagnosis

 CD3+ cells, %

78.10 (66.88–82.00)

 CD3+ cells, /μL

562 (206–752)

 CD3+CD4+ cell, %

26.00 (11.00–44.00)

 CD3+CD4+ cell, /μL

136 (29–383)

 CD3+CD8+ T cells, %

33.20 (28.50–46.00)

 CD3+CD8+ T cells, /μL

224 (122–423)

 CD4/CD8 ratio

0.77 (0.25–10.32)

 CD19+ B cells, %

13.85 (7.44–23.75)

 CD19+ B cells, /μL

104 (22–214)

 CD3−CD16/CD56+ NK cells, %

7.35 (2.80–12.00)

 CD3−CD16/CD56+ NK cells, /μL

47 (14–100)

Survivor follow-up time, days, median (range)

1156 (130–5099)

  1. Categorical variables are presented as numbers (percentiles); continuous variables are presented as median (interquartile range) unless otherwise stated.
  2. ALT alanine aminotransferase, AST aspartate aminotransferase, BM bone marrow, Bu busulfan, CBC complete blood count, DBIL direct bilirubin, HAAA hepatitis‐associated aplastic anaemia, NSAA non- severe aplastic anaemia, PB peripheral blood, PNH paroxysmal nocturnal hemoglobinuria, SAA severe aplastic anaemia, TBIL total bilirubin, VSAA very severe aplastic anaemia.
Back to article page